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Introduction {#sec004}
============

Dengue Virus (DENV) infection is a global health threat that can strain local economies and healthcare resources. Previously unaffected countries are increasingly reporting outbreaks. Only a few countries in Europe and Antarctica have thus far evaded vector borne transmission of DENV \[[@pntd.0007785.ref001]\]. Actual rates of DENV infection are likely under-reported and many cases misclassified \[[@pntd.0007785.ref001]\]. It was recently estimated that 390 million (95% CI: 284--528 million) DENV infections occur annually and 96 million (95% CI: 67--136 million) were symptomatic \[[@pntd.0007785.ref002]\]. Models suggest that by the year 2085, half of the world population may be living in areas at risk of dengue transmission \[[@pntd.0007785.ref003]\]. Indonesia is a DENV endemic region and has experienced a 700-fold increase in incidence over the past 45 years \[[@pntd.0007785.ref004]\]. A clear understanding of the current epidemiology of DENV in Indonesia is critical for design of appropriate public health measures.

DENV infection has a wide range of clinical presentations, from subclinical to debilitating but transient Dengue Fever (DF) to potentially life-threatening Dengue Hemorrhagic Fever (DHF) and Dengue Shock Syndrome (DSS). Atypical presentations are categorized as expanded dengue syndrome \[[@pntd.0007785.ref005]\]. Diagnosis of DENV infection in Indonesia is typically based on clinical presentation, common laboratory evaluation, and rapid diagnostic tests. Specific DENV laboratory confirmation is not usually pursued. Since care for DENV infection is supportive, diagnostic inaccuracy can result in inappropriate treatment, including administration of unnecessary antibiotics for cases attributed to other infections and forgoing of needed antibiotics when other infections are presumed to be dengue. Inappropriate clinical management and inappropriate use of antimicrobials may contribute to increased morbidity, mortality and treatment cost, as well as promote antibiotic resistance.

To better understand the current epidemiology of dengue in Indonesia, cases of presumed and laboratory identified dengue from a cohort study on febrile illnesses requiring hospitalization in Indonesia were characterized. Approaches for assessing dengue infection, genetic characterization, and their public health implications were considered.

Methods {#sec005}
=======

Participants {#sec006}
------------

Patients presumed to have DENV infection based on clinical presentation or found to have DENV infection by subsequent laboratory testing were identified from the Etiology of Acute Febrile Illness Requiring Hospitalization (AFIRE) cohort study, conducted by the INA-RESPOND (Indonesia Research Partnership on Infectious Diseases) network \[[@pntd.0007785.ref006]\] in Indonesia from 2013 to 2016. The AFIRE study recruited patients who presented to hospitals for evaluation of acute fever, were at least one year old, were hospitalized within the past 24 hours, and had not been hospitalized within the past three months. Clinical information and biological specimens were collected at enrollment, 14--28 days after enrollment, and three months after enrollment.

Sites {#sec007}
-----

Patients were recruited to the AFIRE study from eight tertiary hospitals in seven cities in Indonesia: Bandung, Denpasar, Jakarta, Makassar, Semarang, Surabaya and Yogyakarta ([Fig 1](#pntd.0007785.g001){ref-type="fig"}). All study sites contributed cases by diagnosing DENV clinically and/or using laboratory diagnostics (NS1 and/or serology test and/or rapid diagnostic test using different manufacturer).

![Geographic distribution and rates of DENV cases.\
Red dots show study site location. The number of fever cases and acute Dengue infections (percent) at each site are shown below the site name. Bars show the proportion of patients with (red bars) and without (blue bars) prior exposure; white stripes pattern inside the bars shows the subset who experienced acute infection. Note: Nine subjects^a^ had no acute specimens for exposure prior to enrollment: 1 subject in Yogyakarta^b^, 7 subjects in Surabaya^c^, and 1 subject in Makassar^d^. Map source: Wikimedia Commons Atlas of the World *\[Atlas of Indonesia\]*. Available from: <https://commons.wikimedia.org/wiki/Atlas_of_Indonesia#/media/File:Map_of_Indonesia_Demis.png> \[Accessed 23 September 2019\].](pntd.0007785.g001){#pntd.0007785.g001}

Testing algorithm for dengue diagnosis at INA-RESPOND reference laboratory {#sec008}
--------------------------------------------------------------------------

Subjects with acute and convalescent (at least two-weeks apart) plasma were first screened for dengue infections using DENV IgM and IgG by ELISA, followed by DENV NS1 and RT-PCR. Acute plasma from subjects with single specimens were tested using DENV IgM and IgG by ELISA, DENV NS1 and RT-PCR.

Reference laboratory procedures {#sec009}
-------------------------------

### Enzyme-linked Immunosorbent Assay (ELISA) {#sec010}

Assays were conducted using Focus Dengue IgM capture/IgG indirect and Antigen NS1 ELISA (Focus Diagnostics, CA, USA). This is a qualitative assay targeting IgM and IgG antibodies to DENV and NS1 DENV antigen. Absorbance was measured at a wavelength of 450 nm on a microplate reader. The index value was calculated by dividing the sample absorbance by OD cut-off. Index \<1.0 was considered negative, Index \>0.9 to \<1.0 was considered borderline, and Index \>1.0 was considered positive \[[@pntd.0007785.ref007]\].

### Viral RNA Extraction {#sec011}

Viral RNA was extracted from 140 μl plasma using the QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany). Viral RNA was eluted in 60 μl of AVE buffer.

### Dengue serotype determination using the multiplex semi-nested reverse transcription polymerase chain reaction (Msn RT-PCR) {#sec012}

Dengue serotypes were determined by Msn RT-PCR \[[@pntd.0007785.ref008]\] targeting a region encompassing the C-prM gene of DENV with the One-Step RT-PCR Kit (Qiagen, Hilden, Germany) in an Applied Biosystems ProFlex PCR System (Thermo Fisher Scientific, MA, USA). The Msn RT-PCR product was visualized in a 1.5% agarose gel electrophoresis alongside a 100-bp DNA ladder (Invitrogen, CA, USA). The amplicon size for determination of serotypes are 482 bp, 119 bp, 290 bp, and 392 bp for DENV-1, DENV-2, DENV-3, and DENV-4 \[[@pntd.0007785.ref008]\], respectively.

### Dengue genotype determination based on nucleotide sequencing of the Envelope (E) gene {#sec013}

Specimens positive by Msn RT-PCR were selected randomly based on serotype distribution at each site to represent geographical and temporal distribution for sequencing using methods that have been published previously \[[@pntd.0007785.ref009]--[@pntd.0007785.ref011]\]. Viral RNA was converted to complementary DNA (cDNA) using the SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen, CA, USA) according to the manufacturer's instructions, then amplified by PCR at a region covering the structural (*capsid-pre-membrane/membrane-envelope* (C-prM/M-E)) genes using the Platinum^TM^ SuperFi^TM^ DNA Polymerase (Invitrogen, CA, USA). The amplification primers consist of D1F751 and D1R2581 for DENV-1 \[[@pntd.0007785.ref009]\], D2F798 and D2R2516 for DENV-2 \[[@pntd.0007785.ref010]\], D3F791 and D3R2492 for DENV-3 \[[@pntd.0007785.ref009]\], and D4s1c and D4a18 for DENV-4 \[[@pntd.0007785.ref012]\], which resulted in DNA fragments of sizes 1831-bp, 1719-bp, 1702-bp, and 2550-bp for DENV-1, DENV-2, DENV-3, and DENV-4, respectively. DNA sequencing was performed on the purified PCR product by a contracted company (1st Base, Malaysia) using sequencing primers covering the structural region of dengue viruses ([S1 Table](#pntd.0007785.s003){ref-type="supplementary-material"}). Chromatograms were edited and assembled using BioEdit 7.2.5 software. Phylogenetic trees describing genotypes within each of DENV serotypes were built using the maximum likelihood (ML) method, based on the *E* gene of DENV, in the Molecular Evolutionary Genetics Analysis version 7 (MEGA 7.0.20) software. The genotype classification scheme was previously described for each serotype \[[@pntd.0007785.ref011], [@pntd.0007785.ref013]--[@pntd.0007785.ref015]\]. Models of nucleotide substitution that best described sequence evolution for each serotype were identified as TN93+G+I for DENV-1 and DENV-2 data sets and TN93+G for DENV-3 and DENV-4 data sets. The strength of tree topology was estimated by bootstrap analysis using 1000 replicates. Trees were unrooted.

### Characterization of DENV mutations {#sec014}

For serotypes that could not be determined with the standard primer set, the TS1~19~(C→T) substitution at primer annealing site was identified. Then a modified TS1: 5'-CGT CTC AGT GAT CCG GGG RC-3' \[[@pntd.0007785.ref016]\] was employed to overcome failure of Msn RT-PCR detection.

Assessment of Dengue infection and clinical categories {#sec015}
------------------------------------------------------

Recent dengue virus infection was confirmed when viral RNA and/or NS1 antigen was detected in an enrollment sample and/or IgM and IgG seroconversion or increased optical density was observed between enrollment and a subsequent time point (14--28 days apart). Positive DENV IgG in acute specimens was considered evidence of DENV exposure prior to enrollment. Confirmed DENV infections were considered primary when DENV IgG antibodies were not detected in acute specimens; and infections were considered secondary when IgG was detected in acute specimens.

Dengue cases were classified according to the 2011 WHO guidelines \[[@pntd.0007785.ref005]\]. Based on plasma leakage (hemoconcentration ≥20%), thrombocytopenia \<100,000/mm^3^, and hemorrhagic manifestations, cases were categorized as DF, DHF I, DHF II, DHF III, or DHF IV. Unusual manifestations such as neurological, hepatic, renal, and other isolated organ involvement were also noted. For analysis purposes, cases were grouped into DF; DHF I and II; or DHF III, IV, and atypical manifestations.

Analysis {#sec016}
--------

All DENV cases confirmed by the reference laboratory were stratified by serotype, and further stratified by year and location; the absolute number of cases in each stratum was reported. Cases that were confirmed by the reference laboratory but missed at the study sites were stratified by the final study site diagnosis; within each stratum, clinical characteristics were summarized using absolute counts and percentages. The difference in rates of severe cases between secondary and primary infections was summarized with a point estimate, and the p-value was calculated using a chi-squared test. Discordant diagnoses were defined as those who were diagnosed with dengue at a site but did not have reference laboratory confirmed dengue, or those who did have reference laboratory confirmed dengue but were not diagnosed with dengue at a site. The contrast in rates of clinically DF patients between missed cases (those with reference laboratory confirmed dengue who were not initially diagnosed with dengue at a site) and correctly diagnosed cases (those with reference laboratory confirmed dengue who were correctly diagnosed with dengue at a site) was summarized with an odds ratio and 95% confidence interval from Fisher's exact test. Statistical analyses were performed using Stata 15.1 (StataCorp LLC).

Ethics {#sec017}
------

The AFIRE study received ethical approval from the IRBs of Faculty of Medicine University of Indonesia/ Cipto Mangunkusumo Hospital (451/PT02.FK/ETIK/2012), Dr. Soetomo Hospital (192/Panke.KKE/VIII/2012), and the National Institute of Health and Research and Development (NIHRD), Ministry of Health, Indonesia (KE.01.05/EC/407/2012). All eligible participants or their legal guardian signed consent before enrolled to the study.

Results {#sec018}
=======

Epidemiology {#sec019}
------------

Four hundred sixty-eight of 1,464 subjects (32%) enrolled in the AFIRE study from 2013 to 2016 had confirmed DENV infection as the cause of acute fever ([Fig 1](#pntd.0007785.g001){ref-type="fig"}). Three hundred sixty-three cases had positive serology and PCR/NS1; 70 cases with only acute specimens available were positive by PCR/NS1; and 35 cases had positive serology only. From 468 cases, 364 cases were identified from 1,158 subjects who had paired specimens, and 104 cases from 306 subjects who only had single specimens. Of 202 subjects who had no evidence of dengue infections, other pathogens were identified in 75 subjects.

Amongst the seven study cities, the highest proportion of DENV cases was diagnosed at Denpasar (52%) and followed by Makassar (34%). Other cities had lower rates of DENV ([Fig 1](#pntd.0007785.g001){ref-type="fig"}). DENV cases occurred year-round, but were more common from January to March ([Fig 2](#pntd.0007785.g002){ref-type="fig"}). The high proportion of dengue infection was consistent across study years, age groups, genders, and sites.

![Dengue cases per month.\
Red dots/area: dengue cases. Black dots/gray area: all fever cases.](pntd.0007785.g002){#pntd.0007785.g002}

DENV patients tended to be young (mean age 19 ±12.4 years) and were more likely to be male (non-significant trend), generally reflecting the AFIRE study population. Clinical syndrome did not differ by dengue serotype ([S2 Table](#pntd.0007785.s004){ref-type="supplementary-material"}).

Serotypes 1--4 were found circulating during the entire study period with predominance of DENV-3 nationally and in most cities, except DENV-1 in Denpasar and DENV-2 in Surabaya. Monthly DENV serotype distributions by city show dynamic variation of predominant serotype ([S1 Fig](#pntd.0007785.s002){ref-type="supplementary-material"}). Two patients were infected with two different serotypes ([Table 1](#pntd.0007785.t001){ref-type="table"}). Phylogenetic analysis of DENV-1 showed clustering in genotype I, but a specimen collected from Bandung in 2013 was genotype IV. DENV-2 specimens tended to cluster in genotype Cosmopolitan. DENV-3 specimens clustered in genotype I. DENV-4 specimens were mostly in genotype II, with a 2015 specimen from Denpasar falling within genotype I ([Fig 3](#pntd.0007785.g003){ref-type="fig"}).

![Phylogenetic trees showing the relationship of DENV identified in AFIRE study.\
The AFIRE DENV *envelope* (E) gene sequences are presented as: Subject Identification Number \| Country \| City \| Year (in bold). The reference E gene sequences retrieved from GenBank are presented as: Accession Number \| Strain (if available) \| Country \| City (if available) \| Year (not bold). The scale presents the number of nucleotide substitutions per site along the branches. The relationships were constructed by the maximum likelihood (ML) method using nucleotide sequences of the E gene (DENV-1, 2, 4 = 1485 bp; DENV-3 = 1479 bp), with 1000 bootstrap replicates. The trees consist of 43 E gene nucleotide sequences from AFIRE specimens (DENV-1 = 12, DENV-2 = 3, DENV-3 = 19, DENV-4 = 9) and other sequences from the GenBank database. The sequences of the AFIRE DENV E gene were submitted to GenBank under accession numbers MK629460 to MK629502. The clustering of genotypes for DENV-1, DENV-2, DENV-3, and DENV-4 referred to the classification that were described earlier \[[@pntd.0007785.ref011], [@pntd.0007785.ref013]--[@pntd.0007785.ref015]\].](pntd.0007785.g003){#pntd.0007785.g003}
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###### Circulating DENV serotypes by study year and site.

![](pntd.0007785.t001){#pntd.0007785.t001g}

                 DENV-1 (n = 103)   DENV-2 (n = 84)   DENV-3 (n = 186)   DENV-4 (n = 21)   Dual serotype (n = 2)   Unknown serotype (n = 72)
  -------------- ------------------ ----------------- ------------------ ----------------- ----------------------- ---------------------------
  **Year**                                                                                                         
  2013           17                 3                 14                 3                                         4
  2014           34                 23                37                 3                 DENV-1&2 (1)            28
  2015           31                 25                71                 4                 DENV-2&3 (1)            18
  2016           21                 33                64                 11                                        22
  **Location**                                                                                                     
  Bandung        12                 9                 36                 3                 DENV-2&3 (1)            13
  Denpasar       44                 15                37                 5                                         10
  Jakarta        11                 7                 22                 3                                         7
  Makassar       9                  10                33                 4                                         12
  Semarang       11                 11                24                 1                                         17
  Surabaya       2                  23                18                 1                 DENV-1&2 (1)            10
  Yogyakarta     14                 9                 16                 4                                         3

Two patients that had two different serotypes are not included in the individual DENV serotype columns.

Clinical severity and mortality {#sec020}
-------------------------------

Based on clinical signs and symptoms from 468 cases of DENV infection, 187 were classified as DF (40%); 270 as DHF grade I and II (57.7%); and 11 cases as DHF grade III and IV or atypical manifestations (2.3%). Seventy-one cases were primary and 397 were secondary infection. The severe cases were more common in secondary than primary infection. While the difference was not statistically significant, our findings add to the body of evidence that secondary infection cases are more prone to becoming severe (2.8% vs. 0%, p\<0.15). Severe cases tended to be DENV-1 (3 cases) and DENV-3 (8 cases). Mortality due to DENV infection was low (3/468; 0.6%). The first case was a 2 year-old boy, with no underlying disease, who had a secondary dengue infection with DENV-3. He presented to the hospital with 6 days of fever, vomiting, ecchymosis, hemoconcentration (44%), leukopenia (3,800/mm^3^), and thrombocytopenia (34,000/mm^3^). He died on day 3 hospitalization with DSS. The second subject was a 23 year-old male with leukemia, presenting with fever, epistaxis, gum bleeding, nausea, leukocytosis (13,000/mm^3^), and thrombocytopenia (23,000/mm^3^). Clinically he was classified as DF with hemorrhagic manifestations. He was hospitalized for 8 days and died with septic shock. DENV-4 was retrospectively detected by the reference laboratory. The third case was a 62 year-old man with COPD who presented with pneumonia. He had normal leukocyte and platelet counts at enrollment. He died on hospital day 3 from complications of intra-cranial hemorrhage and septic shock. DENV-1 was detected in his blood by the reference laboratory.

DENV seroprevalence {#sec021}
-------------------

Almost half (78/194, 40.2%) of AFIRE study participants under age 5 years showed evidence of dengue exposure based on serologic testing. The proportion of patients with prior dengue exposure increased with age to approximately 90% in 12--25 year-old and almost 100% in adults over 25 years.

Discordant diagnoses {#sec022}
--------------------

A total of 88.5% (414/468) of confirmed dengue cases was correctly diagnosed by study sites. In the 54 cases where dengue was misdiagnosed as other diseases, 25 cases (46%) were diagnosed based on site laboratory results and 29 cases (54%) were diagnosed by only clinical symptoms ([Fig 4](#pntd.0007785.g004){ref-type="fig"}). Details on how these 25 cases were diagnosed on sites, dengue tests on sites, how we excluded on-site diagnoses and how dengue was confirmed for these cases are listed in [Fig 4](#pntd.0007785.g004){ref-type="fig"}. Two cases that were diagnosed pulmonary tuberculosis at sites while dengue was confirmed by RT-PCR/NS1 and serology suggested acute dengue infection in subjects with chronic tuberculosis.

![Clinical diagnoses and reference lab confirmation of DENV infections.\
Presumed etiologies of missed DENV infections and actual etiologies of incorrectly presumed DENV infections are shown. Reference laboratory diagnosis was considered the true diagnosis.](pntd.0007785.g004){#pntd.0007785.g004}

Of these 54 cases, dengue rapid tests were performed in 29 cases at sites. In four cases, NS1 was positive but typhoid fever was the site diagnosis as the Tubex test for IgM *Salmonella typhi* was also positive. In total, dengue was considered in the differential diagnosis in 10 of the 54 missed cases. Comorbidities were observed in 12 cases, including pulmonary tuberculosis, COPD, leukemia, thalassemia, chronic otitis, septal defect, and choledochal cyst. Subjects who were incorrectly diagnosed as non-dengue infection had higher odds of being DF than subjects who were correctly diagnosed as dengue infections; 81.5% of missed cases were clinically DF, whereas only 34.5% of those correctly diagnosed as DENV infection were DF (OR 8.3, 95% CI: 4--19.1).

Of the 514 cases clinically diagnosed as DENV infection by sites, 100 (19.5%) were classified by the reference lab as non-dengue; 58 were found to have another pathogen and no pathogen was identified in 42 cases ([Fig 4](#pntd.0007785.g004){ref-type="fig"}). Other confirmed pathogens were *Rickettsia typhi* (20), chikungunya virus (11), *Leptospira spp* (10), *Salmonella typhi/paratyphi* (7), influenza A/B virus (5), measles virus (2), *Klebsiella pneumoniae* (1), entero-pathogenic *Escherichia coli* (1), and Seoul virus (1). Demography, clinical manifestations, hematology, and biochemistry profiles grouped by identified pathogen are shown in [Table 2](#pntd.0007785.t002){ref-type="table"}.

10.1371/journal.pntd.0007785.t002

###### Infection characteristics: Clinical signs and symptoms, hematology and biochemistry profiles.

![](pntd.0007785.t002){#pntd.0007785.t002g}

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Clinical signs and symptoms                          Dengue (414)               Pathogen identified by reference laboratory                                                                                                                    
  ---------------------------------------------------- -------------------------- --------------------------------------------- ---------------------------- --------------------------- --------------------------- --------------------------- ---------------------------
  **Demography, n (%)**                                                                                                                                                                                                                          

  Age ≥ 18 y.o.                                        196 (47)                   15 (75)                                       5 (45)                       8 (80)                      2 (29)                      5 (100)                     4 (80)

  Gender : Male                                        247 (60)                   12 (60)                                       7 (64)                       9 (90)                      5 (71)                      3 (60)                      2 (40)

  **Lab confirmation, n (%)**                                                                                                                                                                                                                    

  PCR/BC and serology                                  299 (72)                   12 (60)                                       8 (73)                       8 (80)                      4 (57)                      0 (0)                       5 (100)

  Serology only                                        115 (28)                   8 (40)                                        3 (27)                       2 (20)                      3 (43)                      5 (100)                     0 (0)

  **Signs and Symptoms, n (%)**                                                                                                                                                                                                                  

  Fever                                                414 (100)                  20 (100)                                      11 (100)                     10 (100)                    7 (100)                     5 (100)                     5 (100)

  Nausea                                               314 (76)                   15 (75)                                       8 (73)                       7 (70)                      5 (71)                      5 (100)                     4 (80)

  Headache                                             241 (58)                   16 (80)                                       5 (45)                       4 (40)                      4 (57)                      3 (60)                      2 (40)

  Vomiting                                             225 (54)                   7 (35)                                        5 (45)                       6 (60)                      4 (57)                      3 (60)                      3 (60)

  Lethargy                                             85 (21)                    4 (20)                                        2 (18)                       2 (20)                      3 (43)                      3 (60)                      2 (40)

  Arthralgia                                           128 (31)                   6 (30)                                        5 (45)                       2 (20)                      3 (43)                      4 (80)                      2 (40)

  Myalgia                                              94 (23)                    7 (35)                                        4 (36)                       1 (10)                      3 (43)                      1 (20)                      0 (0)

  Chills                                               56 (14)                    4 (20)                                        1 (9)                        4 (40)                      0 (0)                       2 (40)                      0 (0)

  Epigastric pain                                      101 (24)                   6 (30)                                        2 (18)                       0 (0)                       3 (43)                      1 (20)                      2 (40)

  Cough                                                63 (15)                    3 (15)                                        5 (45)                       2 (20)                      3 (43)                      5 (100)                     4 (80)

  Diarrhea                                             38 (9)                     1 (5)                                         2 (18)                       4 (40)                      2 (29)                      0 (0)                       2 (40)

  Skin rash                                            7 (2)                      0 (0)                                         0 (0)                        0 (0)                       0 (0)                       0 (0)                       2 (40)

  Constipation                                         19 (5)                     4 (20)                                        1 (9)                        2 (20)                      0 (0)                       0 (0)                       0 (0)

  Altered mental status                                2 (0.5)                    0 (0)                                         0 (0)                        0 (0)                       0 (0)                       0 (0)                       0 (0)

  Dysuria                                              7 (2)                      0 (0)                                         0 (0)                        0 (0)                       0 (0)                       0 (0)                       0 (0)

  Icteric                                              1 (0.2)                    0 (0)                                         0 (0)                        1 (10)                      0 (0)                       0 (0)                       0 (0)

  Triad Rickettsia: fever, headache and rash           5 (1)                      0 (0)                                         0 (0)                        0 (0)                       0 (0)                       0 (0)                       1 (20)

  **Hematology findings: Median (range)**                                                                                                                                                                                                        

  Hb (mg/dl)                                           14.1\                      14.35\                                        13.7\                        13.5\                       12.9\                       15\                         14.6\
                                                       (5.5--20.8)                (11.4--16.2)                                  (11.7--17.1)                 (11.5--15.7)                (11--14.8)                  (10.2--17.5)                (12--14.8)

  Hematocrit (%)                                       41.6\                      40.2\                                         42.7\                        39.3\                       39\                         43.1\                       43.1\
                                                       (15.9--58)                 (33--48.2)                                    (30.7--49.5)                 (32.9--49.4)                (31.3--43)                  (32.9--48.7)                (36--44.9)

  Leukocyte count: /mm^3^                              3,400\                     5,250 (2,200--9,700)                          6,800 (3,400--12,900)        8,100 (5,600--16,500)       5,900 (5,200--8,800)        6,700 (3,300--9,700)        5,000 (2,600--9,300)
                                                       (800--20,100)                                                                                                                                                                             

  Leukopenia\*                                         299 (72)                   7 (35)                                        2 (18)                       0 (0)                       0 (0)                       2 (40)                      2 (40)

  Leukocytosis\*                                       3 (1)                      0 (0)                                         1 (9)                        1 (10)                      0 (0)                       0 (0)                       0 (0)

  **Differential count**                                                                                                                                                                                                                         

      Neutrophil (%)                                   62\                        71.2\                                         82.6\                        90.1\                       72\                         69\                         82.7\
                                                       (3--94.1)                  (53--80)                                      (59--87.3)                   (64--94)                    (63--84)                    (60.3--84.6)                (73.2--89.3)

      Neutrophil count                                 1,857\                     3,821 (1,306--7,566)                          4,573\                       6,272 (4,877--15,031)       4,956 (3,276--6,318)        4,040 (2,791--6,693)        3,689 (1,903--6,340)
                                                       (132--15,275)                                                            (2,261--10,965)                                                                                                  

      Granulocytopenia                                 109 (26)                   2 (10)                                        0 (0)                        0(0)                        0 (0)                       0 (0)                       0 (0)

      Granulocytosis                                   42 (10)                    1 (5)                                         6 (55)                       6 (60)                      2 (29)                      1 (20)                      3 (60)

      Lymphocyte (%)                                   26.2\                      21.8\                                         13\                          7\                          15.4\                       19\                         8.5\
                                                       (4--77.8)                  (13--41)                                      (6.2--31)                    (3.2--28.4)                 (10--28)                    (11.7--31.7)                (5.3--16.3)

      Lymphocyte absolute                              885\                       1,261\                                        915\                         604\                        1,216\                      1,843\                      400\
                                                       (192--7,104)               (504--2,280)                                  (415--1,677)                 (243--2,783)                (590--1,456)                (386--2,123)                (327--430)

      Lymphocytopenia                                  105 (25)                   4 (20)                                        8 (73)                       7 (70)                      3 (43)                      1 (20)                      4 (80)

      Lymphocytosis                                    91 (22)                    2 (10)                                        0 (0)                        0 (0)                       0 (0)                       0 (0)                       0 (0)

  Platelet count                                       88,350 (10,000--452,000)   98,800 (54,000--268,000)                      185,000 (158,700--288,000)   101,500 (45,000--185,000)   143,300 (82,000--264,000)   147,000 (67,700--319,000)   105,200 (48,500--151,000)

  Platelet \<100,000/mm^3^                             256 (62)                   11 (55)                                       0 (0)                        5 (50)                      1 (14)                      2 (40)                      2 (40)

  Platelet \<150,000/mm^3^                             355 (86)                   17 (85)                                       0 (0)                        7 (70)                      4 (57)                      3 (60)                      4 (80)

  Thrombocytopenia (150,000) AND leukopenia (\<5000)   306 (74)                   8 (40)                                        0 (0)                        0 (0)                       0 (0)                       2 (40)                      2 (40)

  **Biochemistry profiles**                                                                                                                                                                                                                      

      Bilirubin \>1 mg/dl                              6/363 (2)                  2/20 (10)                                     0 (0)                        2/10 (20)                   3/7 (43)                    0 (0)                       0 (0)

      Direct bilirubin \>0.4 mg/dl                     21/363 (6)                 6/20 (30)                                     0 (0)                        4/10 (40)                   3/7 (43)                    0 (0)                       0 (0)

      Indirect bilirubin\>0.6 mg/dl                    11/363 (3)                 1/20 (5)                                      0 (0)                        2/10 (20)                   1/7 (14)                    0 (0)                       0 (0)

      SGOT \>45 IU                                     299/363 (82)               6/20\                                         3/11\                        3/10\                       5/7\                        0 (0)                       0 (0)
                                                                                  (30)                                          (27)                         (30)                        (71)                                                    

      SGOT \>100 IU                                    136/363 (37)               2/20\                                         1/11\                        1/10\                       2/7\                        0 (0)                       0 (0)
                                                                                  (10)                                          (9)                          (10)                        (29)                                                    

      SGPT \>35 IU                                     179/363 (49)               6/20\                                         4/11\                        3/10\                       5/7\                        0 (0)                       0 (0)
                                                                                  (30)                                          (36)                         (30)                        (71)                                                    

      SGPT \>100 IU                                    56/363 (15)                3/20 (15)                                     0 (0)                        0 (0)                       1/7 (14)                    0 (0)                       0 (0)

  Urea N \>40 mg/dl                                    8/363 (2)                  0 (0)                                         1/9 (11)                     4/10 (40)                   0 (0)                       0 (0)                       0 (0)

  Creatinine \>1.2 mg/dl                               39/363 (11)                0 (0)                                         2/11 (18)                    5/10 (50)                   0 (0)                       0 (0)                       0 (0)
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Column 2 shows Dengue cases diagnosed at sites and also confirmed by the reference laboratory. Columns 3--8 shows Dengue cases diagnosed at sites, but confirmed due to another pathogen by the reference laboratory.

Mutation analysis {#sec023}
-----------------

Serotype of dengue could not be determined for three specimens using Dengue serotyping primer set in the study \[[@pntd.0007785.ref008]\], although the specimens produced a valid Dengue group amplicon (511-bp) \[[@pntd.0007785.ref008]\] and Flavivirus group amplicon (266-bp) \[[@pntd.0007785.ref017]\]. Sequencing of the 511-bp amplicon of Dengue group RT-PCR products led to identification of DENV-1 by nucleotide BLAST. Multiple sequence alignment (BioEdit, v7.2.5) to other DENV-1 sequences from GenBank (<https://www.ncbi.nlm.nih.gov/genbank/>) showed that the three DENV-1 specimens have a C→T mutation at nucleotide 19 of the TS1 primer annealing site (TS1 (568--586) = 5'-CGT CTC AGT GAT CCG GGG G-3'). The mutation prevents amplification by the TS-1 primer required to generate the relevant DENV-1 amplicon (482-bp) ([Fig 5](#pntd.0007785.g005){ref-type="fig"}). Additional TS1 mutations in our three specimens were identified as TS1~3~(A→G), TS1~13~(G→A), and TS1~16~(C→T).

![Nucleotide substitutions in TS-1 annealing site (nucleotide 568--586) that affected DENV-1 identification.\
Alignment of sequences covering the TS1 annealing region of AFIRE DENV-1 with other DENV-1 recently circulating in Indonesia as well as DENV-1 Cambodia (2001), with the prM sequence of DENV-1 Nauru/74 (GenBank Accession No M23027) as numbering reference in positive strand. Dots show similarity of nucleotides in their respective positions. Black arrow shows direction of amplification. Numbers below TS1 Mod sequence indicate nucleotide position where mismatches between the TS-1 primer and viral RNA template occur. The three AFIRE specimens that have the TS-1 mutation are 5201009, 5801015, and 5801063, the TS-1 annealing site is highlighted in grey. The sequences were submitted to GenBank under accession numbers MK634700 to MK634702.](pntd.0007785.g005){#pntd.0007785.g005}

Discussion {#sec024}
==========

Our data confirm that dengue is the most common cause of acute febrile illness requiring hospitalization in Indonesia. Our rate of dengue (31.9%) was high relative to previous reports. One study in India did find that DENV infection was responsible for 27% of acute fever syndromes \[[@pntd.0007785.ref018]\]. However, a multicenter surveillance study of acute fever in Asian children showed an incidence of 11.4% \[[@pntd.0007785.ref019]\]. A study in Bandung, Indonesia conducted between 2000--2009 showed 17.4% of febrile cases were due to DENV infection; cases presented with disease severity from DF to DSS \[[@pntd.0007785.ref020]\]. Of note our rate in Bandung was 28% and there was a great deal of variation in rates by region (range 25% - 52%). Our highest rate (52%) occurred in Denpasar, consistent with the Indonesian Ministry of Health dengue data which showed that Bali province had the highest incidence of dengue infection in Indonesia from 2011 to 2015 \[[@pntd.0007785.ref021]\]. Overall rates in our population may differ from previous reports due to inclusion of multiple sites, different settings, diverse age groups, and evolving epidemiology.

Our data also demonstrated that children were exposed to DENV early in life. This finding was consistent across sites. By age 5, more than 40%, and by age of 12, more than 90% showed serologic evidence of prior exposure. Our results are consistent with prior studies of sero-prevalence in Indonesian children, which have shown that 33.8% of children younger than 4 years and 89% of people older than 14 years had been exposed \[[@pntd.0007785.ref020], [@pntd.0007785.ref022]\]. Though sero-prevalence varies amongst countries \[[@pntd.0007785.ref022], [@pntd.0007785.ref023]\], other dengue-endemic Asian countries also show high sero-prevalence by adulthood \[[@pntd.0007785.ref024]--[@pntd.0007785.ref026]\]. These data are important for vaccine programs as the immunity from previous dengue infection can increase the risk of severe infection. The finding that seronegative vaccinees have an increased risk of hospitalized or severe dengue manifestation starting about 30 months after the first DENV vaccine dose has led the WHO to update its recommendations on DENV vaccination \[[@pntd.0007785.ref027]--[@pntd.0007785.ref031]\].

The sensitivity of dengue diagnosis by sites was good, with 88.5% of reference laboratory confirmed dengue cases correctly diagnosed at study sites. On the other hand, 10% of reference laboratory determined non-dengue cases were diagnosed as dengue by study sites. In most non-dengue cases, clinicians diagnosed dengue despite negative dengue rapid tests and/or non-specific clinical presentations. Over-diagnosis of dengue is consistent with prior reports, which showed even higher rates of over-diagnosis during dengue outbreaks \[[@pntd.0007785.ref032], [@pntd.0007785.ref033]\]. Poor availability of rapid diagnostics for other pathogens may contribute to this phenomenon.

The diagnosis of dengue was missed in 54 (11.5%) cases. In most of these, dengue had been considered and then ruled out based on rapid testing. Clinicians often requested only the NS1 antigen or the IgM/IgG rapid tests. Difficulty in interpreting these results without accurate information about onset of illness may have contributed to the missed diagnoses. In the two fatal cases, comorbidities may have influenced the clinical and laboratory findings, confounding the diagnosis. Most of the missed cases (44/54, 81.5%) were mild (DF), suggesting that in the absence of typical presentations (hemoconcentration, severe thrombocytopenia, bleeding manifestation, or shock), and/or incompletely performed dengue rapid diagnostic test, clinicians may overlook dengue as a cause of fever \[[@pntd.0007785.ref034]\].

Dengue diagnostic inaccuracy may reflect overlap of the dengue clinical syndrome with that of several other infections, suggesting the need for increased awareness of the differential for dengue. Consideration should be given to routine use of diagnostic criteria such as the WHO 2012 criteria \[[@pntd.0007785.ref035]\], which considers clinical parameters, hematology, and dengue diagnostics, to improve diagnostic accuracy. Incorrectly attributing another condition to dengue, which is managed supportively, can result in non-administration of necessary medication and hence worse outcomes. Alternatively, mistaking dengue for bacterial infection can engender unnecessary use of antibiotics and potential development of resistance. Factors contributing to diagnostic inaccuracy merit additional investigation.

DENV infection in Indonesia tended to affect productive age patients and showed a non-significant predisposition for males, consistent with prior reports \[[@pntd.0007785.ref021], [@pntd.0007785.ref036]\]. A slightly higher proportion of males to females was also observed in the national Indonesia data registry for dengue during each of the 5 data collection years \[[@pntd.0007785.ref021]\].

All four DENV serotypes were identified at all study sites with a predominance of DENV-3 (46.8%) and DENV-1 (26.1%), except in Surabaya where DENV-2 predominated. Previously, Surabaya had shown more DENV-1, which circulated widely in 2012 \[[@pntd.0007785.ref037]\]. Evaluation of monthly DENV serotype distributions at each site demonstrates that the predominant DENV serotype actually is very dynamic ([S1 Fig](#pntd.0007785.s002){ref-type="supplementary-material"}). This may explain differences in predominant DENV serotype in our study compared to previous reports from certain cities. For example, a prior study from Denpasar conducted from March to May 2015, overlapping with our study period, found that DENV-3 is predominant \[[@pntd.0007785.ref038]\]. Our data agree that the predominant serotype during March to May 2015 was DENV-3, though the overall predominant serotype in Denpasar is DENV-1. It has been shown that the predominant serotype may vary between DENV-1 and DENV-3 \[[@pntd.0007785.ref020], [@pntd.0007785.ref037]--[@pntd.0007785.ref041]\], though we found that predominant serotype fluctuates between DENV-1 and DENV-2 in Surabaya. Shifting of predominant serotype is associated with immune alterations in the population \[[@pntd.0007785.ref042]\], although it is unclear if this is occurring in Indonesia. Furthermore, two of our cases showed dual serotype infection, which has been reported in endemic areas \[[@pntd.0007785.ref043]--[@pntd.0007785.ref045]\]. This may impact clinical presentation and is considered a major risk factor for dengue with higher severity and mortality \[[@pntd.0007785.ref043], [@pntd.0007785.ref046]--[@pntd.0007785.ref048]\]. Epidemiology and clinical profiles of DENV infection did not vary by serotype in our study, although this has been reported in other studies in Indonesia \[[@pntd.0007785.ref004], [@pntd.0007785.ref037], [@pntd.0007785.ref038]\]. High dengue prevalence amongst febrile hospitalized patients, its impact on productive populations and identification of patients with dual dengue infection suggesting that dengue serotypes may circulate simultaneously underscore the need for effective public health approaches to controlling disease.

Severe dengue occurred with secondary DENV-1 and DENV-3 infection. It is known that secondary infections are more likely to be associated with severe disease than primary infections. In a meta-analysis demonstrating that likelihood of severe dengue varies amongst serotypes, primary infection with DENV-3 and secondary infection with DENV-2, DENV-3, and DENV-4 were more likely to result in severe dengue in South East Asia \[[@pntd.0007785.ref049]\] than primary infection with other serotypes or secondary infection with DENV-1. Our results suggest that secondary DENV-1 infection might be more likely than previously realized to cause severe dengue in Indonesia.

Characterization of the DENV E gene informs transmission dynamics, as genotypic variation within serotypes can be a major determinant of epidemics \[[@pntd.0007785.ref050]\]. Shift in genotype predominance has been associated with alterations in immunity against infecting virus and mosquito transmission patterns \[[@pntd.0007785.ref051]\]. During our three-year study (2013--2016), we identified the circulation of both the predominant DENV-1 genotype I and DENV-1 genotype IV. This is consistent with earlier studies showing predominant circulation of DENV-1 genotype I in the recent years, shifting from predominance of DENV-1 genotype IV in the earlier years \[[@pntd.0007785.ref020], [@pntd.0007785.ref041], [@pntd.0007785.ref052]\]. This genotype transition pattern might be associated with the faster replication rate of genotype I compared to genotype IV \[[@pntd.0007785.ref041]\]. There was no change for the circulating DENV-2 and DENV-3 genotypes. DENV-2 genotype Cosmopolitan, the only circulating genotype for DENV-2 in Indonesia \[[@pntd.0007785.ref020], [@pntd.0007785.ref041], [@pntd.0007785.ref053]\], was observed in our cohort. The Cosmopolitan genotype has a wide geographical distribution, spanning from Asia to Africa \[[@pntd.0007785.ref050]\]. DENV-3 genotype I, which is endemic in Indonesia, Malaysia, the Philippines and the South Pacific Islands \[[@pntd.0007785.ref014]\], and has been shown to circulate dating back to the 1970s, was the only DENV-3 genotype found in this study. Besides DENV-4 genotype IIa that circulated at all sites, a specimen collected from Bali in 2015 was grouped into DENV-4 genotype I, suggesting the first observation of DENV-4 genotype I in Indonesia. DENV-4 genotype I was identified in the Philippines, Thailand, Malaysia, and Srilanka during 1960s-1980s. The observation of DENV-4 genotype I in Bali marks the introduction or possible reemergence of an old strain. This observation merits deeper investigation of the circulation of DENV-4 as genotype shift is closely related to evolving epidemic characteristics.

We herein report DENV-1 virus with TS1~3~(A→G), TS1~13~(G→A), TS1~16~(C→T), and TS1~19~(C→T) substitutions in the annealing site of the TS1 primer (nucleotide 568--586). TS1~19~(C→T) prevents successful DENV-1 serotype determination, as also observed from DENV-1 strains in Cambodia \[[@pntd.0007785.ref016]\]. We indeed observed TS1~19~(C→T) in DENV-1 from a 1998 DHF case in Indonesia (DENV-1 98901518, GenBank accession number AB189120). However, TS1~19~(C→T) that was identified in three DENV-1 from this study (5201009, 5801015, 5801063) are not identical to 98901518 since they have three additional mutations within the TS1 annealing site that were not observed in 98901518. Continuous monitoring for genomic mutations may be warranted because failure in serotype determination might mask the true prevalence of circulating DENV. Clinical implications of TS1~19~(C→T) substitutions were not evident based on our data.

Our study had several limitations. The study was not designed as a dengue evaluation and included only febrile hospitalized patients. Since dengue can be subclinical or mild, and may not require hospitalization, generalizability of our findings is limited. Furthermore, management of cases was determined by the site clinicians; it was not standardized nor was it assessed in detail. Thus, it is difficult to infer causality with regards to patient outcomes. However, our study may be the first to evaluate in detail the challenges of confirming dengue in a resource limited setting with multiple other endemic pathogens that have overlapping manifestations. Finally, as the mutation rate of DENV is high, the gel-based RT_PCR method that we used might miss several dengue cases. This might also be one of the reasons that we could not determine DENV serotypes in 72 subjects besides the viremic phase that had passed when blood was collected. However, the serotype detection rate (85%) in our study was comparable with other studies that used RT-PCR method \[[@pntd.0007785.ref054], [@pntd.0007785.ref055]\].

DENV is a common etiology of acute fever amongst patients presenting for hospitalization in Indonesia. DENV infection diagnostic accuracy at clinical sites merits optimization since misdiagnosis of DENV infection can adversely impact management and outcomes. Furthermore, mutations may confound diagnosis. Clinicians should consider following diagnostic algorithms that include DENV confirmatory testing and policymakers should prioritize development of laboratory capacity for diagnosis of DENV and other common pathogens.
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